Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial

BACKGROUND: Chronic wounds (e.g. diabetic foot ulcers) reduce the quality of life, yet treatments remain limited. Glucocorticoids (activated by the enzyme 11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1) impair wound healing. OBJECTIVES: Efficacy, safety, and feasibility of 11β-HSD1 inhibition for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajjan, R A, Hensor, E M A, Del Galdo, F, Shams, K, Abbas, A, Fairclough, R J, Webber, L, Pegg, L, Freeman, A, Taylor, A E, Arlt, W, Morgan, A W, Tahrani, A A, Stewart, P M, Russell, D A, Tiganescu, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942338/
https://www.ncbi.nlm.nih.gov/pubmed/35113805
http://dx.doi.org/10.1530/EJE-21-1197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942338/
https://www.ncbi.nlm.nih.gov/pubmed/35113805
http://dx.doi.org/10.1530/EJE-21-1197

Ejemplares similares